Skip to main content
. 2012 Jan 12;7(1):e30143. doi: 10.1371/journal.pone.0030143

Figure 4. NaBu- resistant MDA-MB-231 cells displayed a high tumor initiation ability in vivo.

Figure 4

Intact MDA-MB-231 and NaBu- resistant MDA-MB-231 cells were transplanted into NOD/SCID mouse. By the day of 28th, the tumor volume were significantly different. Moreover, tumor became palpable as early as on the 5th days in the NaBu- resistant MDA-MB-231 cell transplanted group whereas on the 10th day in the control group(A). Compared with NaBu treated intact cells, or with MET knock down cells, tumor volume was significantly smaller in NaBu treated MET knock down cell transplanted group (A). The tumor incident data were collected on the 30th day after transplanting cancer cells. The NaBu- resistant MDA-MB-231 cell transplanted group resluted in a similar tumor incident rate as the intact MDA-MB-231 group(85%). Down regulation of MET with a treatment of NaBu leads to decrease the tumor incident rate effectively(18%), although con siRNA teated group resulted in a similar tumor incident rate with the intact cancer cell group(83%). *P<0.05.